文献速递慢性肾脏病

每肾小球足细胞数量偏低与进展性慢性肾脏病相关

Lower Podocyte Number per Glomerulus Associates With Progressive CKD.
PubMed 文献 · Kidney Int Rep · 2025-06-11

研究纳入2000至2021年因肿瘤行根治性肾切除术且间质纤维化与肾小管萎缩小于10%的患者,比较35例进展性慢性肾脏病病例与35例年龄性别匹配对照的足细胞测量指标。结果显示病例组足细胞数量与密度、壁层上皮细胞密度均低于对照,校正多种因素后足细胞数量与密度仍与进展性慢性肾脏病相关。

要点

  • 根治性肾切除术后间质纤维化与肾小管萎缩小于10%者中,进展性慢性肾脏病病例足细胞数量与密度低于对照。
  • 校正肾脏病危险因素、肾功能、肾小球体积及肾硬化程度后,足细胞数量与密度仍与进展性慢性肾脏病相关。
  • 足细胞数量偏低与多项肾硬化指标相关,且关联在不同皮质深度间无实质性差异。

核心结论

  • 每肾小球足细胞数量偏低与进展性慢性肾脏病的发生相关,且独立于慢性肾脏病危险因素、肾功能、肾小球体积及肾硬化严重程度。

研究设计与样本

  • 研究为纵向临床研究,纳入2000至2021年因肿瘤行根治性肾切除术且组织学间质纤维化与肾小管萎缩小于10%的患者。
  • 进展性慢性肾脏病定义为肾切除术后基线估算肾小球滤过率之后开始透析、肾移植、持续估算肾小球滤过率低于10 ml/min per 1.73 m2或持续估算肾小球滤过率下降30%。
  • 每例进展性慢性肾脏病病例按年龄性别与同一随访时间无进展性慢性肾脏病的对照匹配。
  • 采用免疫组化与体视学测定足细胞测量指标(每肾小球数量、密度和细胞体积)及壁层上皮细胞测量指标(每肾小球数量和密度)。

主要发现

  • 共研究35例慢性肾脏病病例和35例对照。
  • 病例组与对照组体重指数无显著差异(均值29.1 vs 28.2 kg/m2,P = 0.88),肾小球簇体积与壁层上皮细胞数量亦无显著差异。
  • 病例组足细胞数量、足细胞密度和壁层上皮细胞密度均低于对照组。
  • 足细胞数量偏低与多项肾硬化测量指标相关。
  • 校正分析中足细胞数量与足细胞密度均与进展性慢性肾脏病相关,且这些关联在不同皮质深度间无实质性差异。

关键数值与推荐

  • 进展性慢性肾脏病判定标准包括开始透析、肾移植、持续估算肾小球滤过率低于10 ml/min per 1.73 m2或持续估算肾小球滤过率下降30%。
  • 纳入要求组织学间质纤维化与肾小管萎缩小于10%。
  • 校正模型一调整肾小球簇体积、肾小球硬化、间质纤维化与肾小管萎缩及动脉硬化。
  • 校正模型二调整年龄、性别、糖尿病、体重指数、高血压、估算肾小球滤过率及蛋白尿。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Podocyte depletion may play an important role in chronic kidney disease (CKD); however, longitudinal clinical studies are lacking in populations without obesity-related glomerulopathy. METHODS: Patients studied underwent radical nephrectomy for tumors between 2000 and 2021 and had < 10% interstitial fibrosis and tubular atrophy (IFTA) on histology. Cases who developed progressive CKD were identified by the onset of dialysis, kidney transplantation, sustained estimated glomerular filtration rate (eGFR) < 10 ml/min per 1.73 m2, or sustained 30% eGFR decline after the postnephrectomy baseline eGFR. Each case of progressive CKD was age-sex-matched to a control without progressive CKD at the same follow-up time. Podometric measures (number/glomerulus, density, and cell volume) and parietal epithelial cell (PEC) measures (number/glomerulus and density) were determined with immunohistochemistry and stereology. The risk of progressive CKD with podometric measures was assessed, adjusting for glomerular tuft volume, glomerulosclerosis, IFTA, and arteriosclerosis (all determined by morphometry) or adjusting for age, sex, diabetes mellitus, body mass index (BMI), hypertension, eGFR, and proteinuria. RESULTS: There were 35 CKD cases and 35 controls studied. Cases versus controls did not differ significantly by BMI (mean: 29.1 vs. 28.2 kg/m2, P = 0.88), glomerular tuft volume, or PEC number, but had lower podocyte number, lower podocyte density, and lower PEC density. Lower podocyte number correlated with several nephrosclerosis measures. In adjusted analyses, podocyte number and podocyte density associated with progressive CKD and these associations did not substantively differ by cortex depth. CONCLUSION: Low podocyte number per glomerulus is associated with the development of progressive CKD independent of CKD risk factors, kidney function, glomerular volume, and nephrosclerosis severity.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Denic A, Shaik AA, Fareeduddin SK, et al. Lower Podocyte Number per Glomerulus Associates With Progressive CKD. Kidney Int Rep. 2025. PMID: 40980642. doi:10.1016/j.ekir.2025.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。